A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
Phytonutrients (flavonoids, phenolic acids, terpenes, sulfur compounds) are plant compounds not classified as vitamins or minerals that exert biological effects in humans. Polyphenols (quercetin, resveratrol, catechins, anthocyanins) act as antioxidants, activate nuclear receptors (AhR, Nrf2), and modulate inflammation via microbiota-derived metabolites. Bioavailability is typically low (1–5%), with metabolism by gut microbiota producing active metabolites. Epidemiologic evidence links high phytonutrient intake (from whole plants) to reduced chronic disease risk, but isolated phytonutrient supplements show inconsistent benefits.
Compare polyphenol content and bioavailability across plant foods; examine how cooking, fermentation, and gut microbiota affect metabolite production.
From your study of antioxidants and phytochemicals, you know that plants produce a vast array of non-nutritive compounds with biological effects in animals. The phytonutrient story goes deeper: these compounds are not random metabolic byproducts but sophisticated chemical signals that evolved for plant defense, pollinator attraction, and UV protection — and they happen to interact meaningfully with human biochemistry.
The polyphenol class is the most clinically studied subset. Polyphenols are characterized by multiple phenol rings and organized into major subclasses: flavonoids (quercetin in onions, catechins in green tea, anthocyanins in berries), phenolic acids (caffeic acid in coffee, ferulic acid in grains), stilbenes (resveratrol in grapes), and lignans (in flaxseed). Each class has distinct structural features that determine its biological targets. Flavonoids modulate signaling through activation of Nrf2 — a transcription factor that upregulates the body's own antioxidant enzyme systems — and inhibition of NF-κB, a master regulator of inflammatory gene expression. The key insight is that polyphenols act less as direct antioxidants scavenging free radicals and more as signaling molecules that prime the body's endogenous defenses.
Bioavailability is the central practical challenge. Most polyphenols are poorly absorbed in their native dietary form — 1–5% bioavailability is typical. They arrive in the colon largely intact, where gut microbiota transform them into smaller metabolites that may be pharmacologically active: urolithins from ellagic acid, equol from soy isoflavones, and various short-chain phenolics from quercetin breakdown. This means the "dose" that reaches target tissues depends not just on dietary intake but on an individual's gut microbiome composition. Two people eating identical diets can have dramatically different polyphenol metabolite profiles, which partly explains why intervention studies show wide individual variation in response.
The epidemiological evidence is robust but the supplementation evidence is consistently disappointing. High dietary intake of polyphenol-rich whole foods — berries, green tea, extra-virgin olive oil, dark chocolate, cruciferous vegetables — associates with lower risk of cardiovascular disease, type 2 diabetes, and certain cancers in large cohort studies. But when investigators isolate the presumed active compound and test it in a pill, effects attenuate or disappear. The likely explanation is food matrix synergy: whole foods provide fiber that feeds the microbiome enabling metabolite production, multiple phytonutrients working through complementary pathways, and macronutrient context affecting absorption kinetics. A quercetin supplement misses all of this. The practical lesson is that "eat the food" is evidence-based advice in a way that "take the extract" is not — a distinction that matters enormously given the commercial pressure to sell phytonutrient supplements.
No topics depend on this one yet.